Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617

The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving 177Lu-PSMA-617. METHODS: 109 mCRPC patients treated with a median of 3 cycles of 177Lu-PSMA-617 were included. Data were analyzed acc...

Verfasser: Kessel, Katharina
Seifert, Robert
Schäfers, Michael
Weckesser, Matthias
Schlack, Katrin
Bögemann, Martin
Rahbar, Kambiz
FB/Einrichtung:FB 05: Medizinische Fakultät
Dokumenttypen:Artikel
Medientypen:Text
Erscheinungsdatum:2019
Publikation in MIAMI:07.07.2020
Datum der letzten Änderung:31.07.2020
Angaben zur Ausgabe:[Electronic ed.]
Quelle:Theranostics 9 (2019) 17, 4841-4848
Schlagwörter:prostate cancer; mCRPC; 177Lu-PSMA-617; PSMA; radioligand therapy; second line chemotherapy; cabazitaxel; metastases
Fachgebiet (DDC):610: Medizin und Gesundheit
Lizenz:CC BY 4.0
Sprache:English
Förderung:Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF-Dokument
URN:urn:nbn:de:hbz:6-90179571208
Weitere Identifikatoren:DOI: 10.7150/thno.35759
Permalink:https://nbn-resolving.de/urn:nbn:de:hbz:6-90179571208
Verwandte Dokumente:
Onlinezugriff:artikel_rahbar_2019.pdf
zusatzmaterial_rahbar_2019.pdf
Daten herunterladen:ZIP-Datei

The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving 177Lu-PSMA-617. METHODS: 109 mCRPC patients treated with a median of 3 cycles of 177Lu-PSMA-617 were included. Data were analyzed according to OS as well as PSA response patterns with regard to prior therapies, laboratory biomarkers and metastatic extent in univariate as well as multivariate Cox's proportional hazards models. PSA decline was assessed using the lowest PSA levels after the first cycle of therapy (initial PSA response) and during the entire observation period (best PSA response). RESULTS: In total, 54 patients (49.5%) died during the observation period. First and second line chemotherapy were performed in 85% and 26%, and Abiraterone and Enzalutamide were administered in 83% and 85%, respectively. Any initial PSA decline occurred in 55% while 25% showed a PSA decline of ≥50%. The median estimated OS was 9.9 months (95% CI: 7.2-12.5) for all patients. Any initial decline of PSA was associated with significantly prolonged OS (15.5 vs. 5.7 months, p = 0.002). Second line cabazitaxel chemotherapy (6.7 vs. 15.7 months, p = 0.002) and presence of visceral metastases (5.9 vs. 16.4 months, p